ArticlePoultry science2025
Utilization of edible poultry slaughter residues: A chicken-liver hydrolysate with glucose-lowering ability and upregulating glycogenesis in type II diabetes.
Article in Poultry science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Protein hydrolysates derived from poultry by-products as nutraceuticals: Bioactive potential, limitations, safety considerations, and commercialization perspectives.Poultry science · 2026Review
- Serum metabolomics identifies metabolic changes in obese cats fed enzymatically hydrolyzed poultry byproduct meal.Journal of veterinary internal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 10,000 metric tons of broiler livers are yielded every year in Taiwan. However, due to unpleasant odor and health concern, these livers are typically discarded as waste in the slaughtering stream in most developed or developed countries. In alignment with global agrocycle policies, a biofunctional chicken-liver hydrolysate (CLH) has been developed. This study was to investigate the effects of CLHs on glucose homeostasis and complications in type II diabetes. Insulin resistance was induced in liver (FL83B) and muscle (C2C12) cells using 30 and 20 ng TNF-α/mL, respectively, resulting in decreased glucose uptake and lower expressions of IRβ, p-Akt/Akt, and p-GSK3/GSK. CLH supplementation significantly upregulated (p<0.05) glucose uptakes and these proteins. In db/db mice, CLH supplementation improved insulin resistance, as shown by OGTT assay, HOMA-IR value and serum glucose levels, while also reducing serum lipids and liver damage indices (p<0.05). Additionally, CLH ameliorated (p<0.05) decreased hindlimb-gastrocnemius weight, and liver lipid contents, oxidative stress (sera and liver) and inflammatory cytokines. Increased glycogen accumulation was visualized in PAS-stained liver and hindlimb tissues of db/db mice supplemented with CLHs, consistent with upregulated glycogenesis in TNF-α-induced liver and muscle cells through the IRβ-Akt-GSK3 pathway. These findings suggest CLH may offer a mitigation against hyperglycemia and associated complications in type II diabetes, while also highlighting a sustainable solution for utilizing poultry slaughter residues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.